
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc. has demonstrated significant advancements in its investigational medicines, particularly KSI-101, which has shown a strong efficacy profile with over 50% of patients experiencing a ≥3-line improvement in vision within four weeks and over 90% achieving retinal dryness by week eight. The recent positive results from the GLOW2 trial for tarcocimab tedromer have led to a substantial increase in the probability of success (POS) estimates for both diabetic retinopathy and wet age-related macular degeneration, highlighting the potential for these therapies to address unmet medical needs. Continued positive feedback from key opinion leaders regarding the ABC platform's innovations further enhances the outlook for Kodiak Sciences, supporting expectations for improved clinical outcomes and pivotal trial success in the near future.
Bears say
Kodiak Sciences Inc's outlook appears negative due to significant setbacks experienced by its original conjugated formulations, exemplified by the failures of the Phase 3 GLEAM and GLIMMER trials in diabetic macular edema (DME) and the Phase 2b/3 DAZZLE trial in wet age-related macular degeneration (AMD). Additionally, the company is facing substantial risks, including the possibility that its developmental candidates may not achieve the anticipated peak commercial revenue due to constraints related to market size, penetration rates, and pricing strategies. Another critical concern is the ongoing challenge of securing sufficient capital resources to fund operations and sustain program development and commercialization efforts.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares